TRIB - Trinity Biotech provides business development update for Q2 shares up 8%

Trinity Biotech (TRIB) pops 8% premarket after providing a business development update for Q2 2021. In June 2021, the Company received an update from the WHO on the approval process of TrinScreen HIV. The WHO confirmed that their screening of the submission dossier is complete and the dossier will now move forward to the final assessment phase. The Company is preparing for the automated manufacture of TrinScreen HIV at its facility in Ireland in anticipation of WHO approval. Trinity Biotech is at an advanced stage in the development of a SARS-CoV-2 antigen test, which provides a result in 12 minutes and utilizes an easy-to-use anterior nasal swab sample. COVID-19 Rapid Antibody Test In June 2021, the Company made an EUA application to the FDA for the UniGold SARS-CoV-2 rapid antibody test. This month, the FDA informed that given the volume of EUA requests it has received, it is not currently prioritizing this type of

For further details see:

Trinity Biotech provides business development update for Q2, shares up 8%